• Puma Biotechnology reported third-quarter 2026 net NERLYNX revenue of $54.1 million, up approximately 5% year over year.
• Revenue rose approximately 1% from the second quarter.
• Ex-factory sales totaled 2,818 bottles, down approximately 4% both year over year and sequentially.
• U.S. commercial demand reached 2,899 bottles, up approximately 5% year over year but down approximately 3% sequentially.
• Inventory declined $1.5 million, compared with a $1 million decline in the second quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.